open access

Vol 81, No 9 (2010)
ARTICLES
Get Citation

Human papilloma virus genotyping in women with CIN 1

Witold Kędzia, Agata Józefiak, Dominik Pruski, Wojciech Rokita, Marek Spaczyński
Ginekol Pol 2010;81(9).

open access

Vol 81, No 9 (2010)
ARTICLES

Abstract

Abstract Introduction: Cervical cancer remains a considerable diagnostic and therapeutic problem in Poland. Despite progress in creating an active cancer prevention program in our country, Poland occupies one of the last places in the EU in terms of cervical cancer morbidity and mortality. Supplement of secondary prevention of primary prophylaxis – HPV 16, 18 vaccination, offers hope for improvement of the situation. Epidemiology of individual HPV types differs, depending on the geographical location of the study population. So far in Poland, we have had no reliable data on the participation of selected oncogenic HPV types in the development of cervical pathology. Objective: Identification of the most frequent, oncogenic HPV types in women diagnosed with CIN 1, from the Central and Western Poland. Material: In the course of the conducted studies, genotyping of 13 types of human papilloma virus has been done in 126 HPV DNA-positive women diagnosed with CIN 1. Method: Each cell material in which the presence of HPV DNA identified 13 types of oncogenic human papillomavirus was subsequently subjected to genotyping using the molecular test – Linear Array HPV Genotyping (Roche Diagnostics). Results and conclusion: In women from the Central and Western Poland diagnosed with CIN 1, HPV 16 (53,97%) was the most common, followed by HPV 33 (21.3%), HPV 18 (16.67%), HPV 31 (10.32%), HPV 45 (7.94%), HPV 52 (1.59%). Current HPV vaccines are designed to protect against two of the three most common genotypes, in women diagnosed with CIN 1 in Central and Western Poland.

Abstract

Abstract Introduction: Cervical cancer remains a considerable diagnostic and therapeutic problem in Poland. Despite progress in creating an active cancer prevention program in our country, Poland occupies one of the last places in the EU in terms of cervical cancer morbidity and mortality. Supplement of secondary prevention of primary prophylaxis – HPV 16, 18 vaccination, offers hope for improvement of the situation. Epidemiology of individual HPV types differs, depending on the geographical location of the study population. So far in Poland, we have had no reliable data on the participation of selected oncogenic HPV types in the development of cervical pathology. Objective: Identification of the most frequent, oncogenic HPV types in women diagnosed with CIN 1, from the Central and Western Poland. Material: In the course of the conducted studies, genotyping of 13 types of human papilloma virus has been done in 126 HPV DNA-positive women diagnosed with CIN 1. Method: Each cell material in which the presence of HPV DNA identified 13 types of oncogenic human papillomavirus was subsequently subjected to genotyping using the molecular test – Linear Array HPV Genotyping (Roche Diagnostics). Results and conclusion: In women from the Central and Western Poland diagnosed with CIN 1, HPV 16 (53,97%) was the most common, followed by HPV 33 (21.3%), HPV 18 (16.67%), HPV 31 (10.32%), HPV 45 (7.94%), HPV 52 (1.59%). Current HPV vaccines are designed to protect against two of the three most common genotypes, in women diagnosed with CIN 1 in Central and Western Poland.
Get Citation

Keywords

HPV genotypes, HPV epidemiology, cervical cancer

About this article
Title

Human papilloma virus genotyping in women with CIN 1

Journal

Ginekologia Polska

Issue

Vol 81, No 9 (2010)

Bibliographic record

Ginekol Pol 2010;81(9).

Keywords

HPV genotypes
HPV epidemiology
cervical cancer

Authors

Witold Kędzia
Agata Józefiak
Dominik Pruski
Wojciech Rokita
Marek Spaczyński

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk
tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl